[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microvascular-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microvascular-dysfunction":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,84,114,151,184,215],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100649486","phase-4-hormone-therapy-effects-on-brain-heart-health-during-the-menopausal-transition-100649486",false,"NCT07732452","Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition","HER BRAVE HEART Trial - Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition: A Randomized Feasibility Study","HERBRAVEHEART","Inclusion Criteria:\n\n* Women aged ≥ 45 years.\n* Perimenopausal or postmenopausal, defined as at least one of the following:\n\n  * Perimenopause, defined as menstrual cycle irregularity (changes in cycle length, skipped cycles, or amenorrhea ≥ 60 days) accompanied by vasomotor symptoms consistent with the menopausal transition.\n  * Postmenopause, defined as at least one of:\n\n    * ≥ 12 months of spontaneous amenorrhea, or\n    * bilateral oophorectomy, or\n    * hysterectomy with FSH \\> 40 IU\u002FL when menstrual history is unavailable.\n* Vasomotor symptoms with a negative impact on quality of life, defined as :\n\n  * Recurrent hot flashes (sudden sensations of heat, typically involving the face, neck, or chest, often associated with flushing and\u002For sweating), and\u002For\n  * Night sweats (episodes of excessive sweating during sleep), With associated interference in daily functioning, sleep, or overall quality of life, such that the participant would be an appropriate candidate for systemic menopausal hormone therapy in clinical practice.\n* Presence of at least one cardiovascular risk factor, defined as either:\n\n  * Hypertension (diagnosed hypertension, use of antihypertensive medication, or blood pressure ≥ 140\u002F90 mmHg on screening).\n  * Dyslipidemia (diagnosed dyslipidemia, use of lipid-lowering therapy, LDL ≥ 3.0 mmol\u002FL, or total cholesterol ≥ 5.2 mmol\u002FL).\n  * Type 2 diabetes mellitus, defined as HbA1c ≥ 6.5%, fasting plasma glucose ≥ 7.0 mmol\u002FL, or use of glucose-lowering medication.\n  * Obesity (body mass index ≥ 30 kg\u002Fm²).\n  * Current smoking.\n  * First-degree family history of premature cardiovascular disease, defined as myocardial infarction, stroke, or documented coronary artery disease occurring before age 55 years in a male relative or before age 65 years in a female relative.\n* Eligible for systemic MHT (i.e., no formal contraindication to MHT).\n* Able and willing to undergo research CMR and attend the 12-month follow-up assessment.\n* Able to provide written informed consent.\n* Not currently using systemic MHT at baseline, or willing to discontinue systemic MHT prior to randomization and remain off systemic MHT until allocation and baseline assessments are complete.\n\nExclusion Criteria:\n\n* Prior cardiovascular event or established cardiovascular disease, including myocardial infarction, stroke or TIA, coronary artery disease, heart failure, cardiomyopathy, or clinically significant valvular heart disease.\n* Uncontrolled hypertension or other unstable cardiovascular condition (e.g., unstable angina, decompensated heart failure, uncontrolled arrhythmia).\n* Formal contraindication to systemic menopausal hormone therapy, including estrogen-dependent cancer, unexplained vaginal bleeding, active severe liver disease, severe thrombophilia, antiphospholipid syndrome, prior or active VTE.\n* Standard contraindications to MRI (e.g., MRI-incompatible pacemakers or intracardiac devices, certain metallic implants, metallic foreign bodies in the eye, or severe claustrophobia not manageable).\n* Pregnant.\n* Active cancer on ongoing cardiotoxic chemotherapy.\n* Current use of systemic hormonal therapy outside the study strategy, including systemic menopausal hormone therapy, combined hormonal contraception, or systemic progestin-only contraception, with unwillingness or inability to discontinue prior to baseline and randomization.\n* Ten years or more since menopause, defined as ≥10 years from the final menstrual period or from bilateral oophorectomy\n* Participants currently using combined hormonal contraception or systemic progestin-only contraception who are willing to discontinue must complete a washout period of at least 4 weeks prior to the baseline visit and randomization","FEMALE","45 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this clinical trial is to learn whether it is feasible to conduct a larger study comparing transdermal menopausal hormone therapy (MHT) versus no hormone therapy in menopausal women with vasomotor symptoms (hot flashes and night sweats) and at least one cardiovascular risk factor. The main questions it aims to answer are:\n\n* What proportion of eligible women agree to be randomly assigned to either receive MHT or not?\n* How many participants complete the 12-month follow-up, including repeat heart imaging?\n* Does transdermal MHT affect early changes in heart muscle tissue as measured by cardiac MRI?\n\nResearchers will compare immediate initiation of transdermal estradiol (a skin gel or patch) to a no-hormone therapy strategy to see if MHT influences early cardiovascular and brain-vascular changes over 12 months.\n\nParticipants will:\n\n* Be randomly assigned to start transdermal MHT within 2 weeks, or to use no hormone therapy for at least the first 3 months\n* Undergo a cardiac MRI and retinal eye imaging at the start of the study and again at 12 months\n* Complete cognitive testing and questionnaires about symptoms, sleep, and stress at both visits\n* Provide a blood sample for storage and future analysis of heart and brain health markers\n* Receive follow-up phone calls at 3, 6, and 9 months to review symptoms, medications, and any health changes",[27,28,29,30,31,32,33,34,35],"Menopause","Perimenopause","Vasomotor Symptoms","Cardiovascular Disease Risk Factor","Menopausal Hormone Therapy","Cardiac Remodeling","Myocardial Fibrosis","Microvascular Dysfunction","Cognitive Function Assessment","NOT_YET_RECRUITING","2026-07-23",{"date":39,"type":40},"2026-07-29","ACTUAL",{"date":42,"type":21},"2026-11",{"date":44,"type":21},"2029-01",{"name":46,"class":47},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":83},"100639718","the-role-of-cd34-stem-cells-in-the-pathogenesis-of-takotsubo-syndrome-100639718","NCT07604467","The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome","Effects of CD34+ Stem Cells on Left Ventricular Dysfunction Among Patients With Takotsubo Syndrome","STRESS","Inclusion Criteria:\n\n* Minimum age 18 years\n* Established TTS per InterTak registry criteria\n* Signed consent form\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Ischemic heart disease with at least one complete total occlusion\n* Other concurrent cardiomyopathies\n* Active infectious myocarditis\n* obstructive coronary artery disease\n* Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event\n* Previous interventional coronary artery procedure in the last 6 months before TTS acute event\n* Significant valvular heart disease\n* Significant peripheral artery occlusive disease\n* Active or remitted hematologic malignancy\n* Patients receiving immunosuppressive therapy\n* Significant comorbiditeis affecting patients survival (malignancy)\n* Failure to obtain freely given, informed consent form.","ALL","18 Years",{"count":59,"type":21},40,"OBSERVATIONAL","The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.",[63,34,64,65,66],"Tako Tsubo Cardiomyopathy","CD34+ Stem Cells","Heart Failure","Cardiac Contractility Recovery",[68,69,70,71,72],"Takotsubo syndrome","CD34+ stem cells","heart failure","microvascular dysfunction","cardiac contractility recovery","RECRUITING","2026-05-17",{"date":76,"type":40},"2026-05-22",{"date":78,"type":40},"2021-09-06",{"date":80,"type":21},"2026-12-31",{"name":82,"class":47},"University Medical Centre Ljubljana",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":102,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":83},"100568615","phase-2-palmitic-acid-and-human-microvascular-function-100568615","NCT06683534","Palmitic Acid and Human Microvascular Function","Use of Quercetin to Increase Resiliency to Palmitic Acid in the Human Microvasculature","Inclusion Criteria:\n\n* Obesity (BMI\\>30)\n* Aged 18-40 years\n* English Speaking\n\nExclusion Criteria:\n\n* BMI\\>60\n* Resting SBP ≥180 mmHg or DBP ≥ 110mmHg\n* Pregnancy or breastfeeding.\n* Prior history of myocardial infarction\n* Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)\n* Active mouth sores that affect the buccal mucosa.","40 Years",{"count":59,"type":21},[94],"PHASE2","The goal of this study is to learn how a supplement Quercetin can affect microvascular function.\n\nParticipants will:\n\n* give two blood draws of 5 mL each\n* have a camera placed under the tongue to take pictures of blood vessels\n* have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion\n\nResearchers will compare blood vessel function of those who take estrogen supplements to those who do not.",[34,97,98,99,100,101],"Microvasculature","Cardiovascular Diseases","Cardiovascular Diseases (CVD)","Microvascular Health","Obesity and Overweight",[103,104],"Obesity","Supplement","2026-04-28",{"date":107,"type":40},"2026-04-29",{"date":109,"type":21},"2026-07",{"date":111,"type":21},"2030-12",{"name":113,"class":47},"Medical College of Wisconsin",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":121,"sex":56,"minAge":57,"maxAge":122,"enrollmentInfo":123,"targetDuration":125,"studyType":60,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":83},"100620866","nailfold-capillaroscopy-and-endothelial-biomarkers-in-healthcare-workers-exposed-to-chronic-low-dose-ionizing-radiation-100620866","NCT07363187","Nailfold Capillaroscopy and Endothelial Biomarkers in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","Evaluation of Microvascular Changes by Nailfold Capillaroscopy and Serum ADMA, Von Willebrand Factor, Hs-CRP, and D-dimer Levels in Healthcare Workers Exposed to Chronic Low-Dose Ionizing Radiation","Inclusion Criteria:\n\n* Healthcare workers aged between 18 and 60 years.\n* For the control group: Employment in a healthcare institution with either occupational exposure to low-dose ionizing radiation or no occupational radiation exposure.\n* For the exposed group: chronic occupational exposure to ionizing radiation for at least 3 years.\n* Willingness and ability to provide written informed consent.\n* Ability to comply with study procedures, including nailfold capillaroscopy and blood sample collection.\n\nExclusion Criteria:\n\n* History of cardiovascular disease, cerebrovascular disease, or peripheral vascular disease.\n* Presence of systemic diseases that may affect microvascular structure or endothelial function, including diabetes mellitus, uncontrolled hypertension, dyslipidemia, or chronic kidney disease.\n* Known autoimmune, connective tissue, or systemic inflammatory diseases (e.g., systemic sclerosis, lupus erythematosus, vasculitis).\n* Active infection or acute inflammatory condition at the time of enrollment.\n* Use of systemic medications that may affect endothelial function or microcirculation within the past 4 weeks, including vasodilators, antihypertensive agents, statins, antiplatelet or anticoagulant drugs.\n* Current smoking or history of smoking within the past 6 months.\n* Pregnancy or breastfeeding.\n* History of malignancy or current cancer treatment.\n* Previous finger trauma, surgery, or local conditions affecting the nailfold area that may interfere with capillaroscopic evaluation.",true,"60 Years",{"count":124,"type":21},90,"1 Day","Chronic occupational exposure to low-dose ionizing radiation may lead to subclinical endothelial dysfunction and early microvascular alterations in healthcare workers. Nailfold capillaroscopy is a non-invasive method that allows direct visualization of microcirculatory changes. This observational study aims to evaluate microvascular alterations using nailfold capillaroscopy and to assess their association with serum endothelial and inflammatory biomarkers, including asymmetric dimethylarginine (ADMA), von Willebrand factor (vWF), high-sensitivity C-reactive protein (hs-CRP), and D-dimer levels. Healthcare workers with chronic low-dose radiation exposure will be compared with non-exposed controls. The study seeks to improve understanding of early vascular effects of occupational radiation exposure.",[34,128,129],"Endothelial Dysfunction","Occupational Radiation Exposure",[131,132,133,134,135,136,137,138,139,140],"Nailfold capillaroscopy","Microvascular changes","Low-dose ionizing radiation","Occupational radiation exposure","Healthcare workers","Endothelial dysfunction","Inflammation biomarkers","D-dimer","High-sensitivity C-reactive protein","Asymmetric dimethylarginine","2026-01-22",{"date":143,"type":40},"2026-01-26",{"date":145,"type":21},"2026-02-01",{"date":147,"type":21},"2026-05-01",{"name":149,"class":150},"Istanbul Training and Research Hospital","OTHER_GOV",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":159,"targetDuration":161,"studyType":60,"phases":4,"briefSummary":162,"conditions":163,"keywords":170,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":83},"100600886","comprehensive-coronary-physiology-in-patients-with-angina-with-nonobstructive-coronary-arteries---czech-republic-100600886","NCT07103317","Comprehensive Coronary Physiology in Patients With Angina With Nonobstructive Coronary Arteries - Czech Republic","Comprehensive COROnary PHYSiology Assessment in Patients With Angina With Nonobstructive Coronary Arteries - CZECH Republic (CoroPhys-CZECH)","CoroPhys-CZ","Inclusion Criteria:\n\n* Adults of both sexes older than 18 years\n* Angina symptoms or angina equivalent\n* Referred to cath lab for evaluation of CAD\n* Invasive physiology testing performed (microcirculation testing +\u002F- vasospasm testing)\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Pregnant of nursing\n* No coronary physiology measurements were performed",{"count":160,"type":21},1000,"100 Years","Coronary artery disease (CAD) is a leading cause of morbidity and mortality. While cardiologists have been focused on discrete, visible stenoses of coronary arteries, there is increasing awareness of the importance of microcirculation and vasospastic disorders in causing angina. The microvascular bed is composed of vessels smaller than 400 microns in diameter. Their network is significantly larger than that of the epicardial vessels and serves essential functions, including regulating myocardial blood flow and cellular metabolism.\n\nAngina pectoris, a most frequent symptom of CAD or myocardial ischemia, was assumed to be caused by significant stenosis of the epicardial coronary artery. However, it was found that in over 50% of cases, there was no obstructive CAD, which is described as angina with no obstructive coronary arteries (ANOCA) or ischemia with no obstructive coronary arteries (INOCA), according to the clinical setting.",[164,165,166,34,167,168,169],"ANOCA","ANOCA - Angina With Non-obstructive Coronary Arteries","MINOCA","Microvascular Angina","Vasospastic Angina","Acetylcholine",[164,171,166,172,167,168,173,174],"INOCA","Coronary Microvascular Dysfunction","Acetylcholine Testing","Coronary Termodilution","2025-08-01",{"date":177,"type":40},"2025-08-05",{"date":179,"type":40},"2023-04-20",{"date":181,"type":21},"2030-01-01",{"name":183,"class":47},"University Hospital, Motol",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":56,"minAge":57,"maxAge":4,"enrollmentInfo":192,"targetDuration":194,"studyType":60,"phases":4,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":83},"100572611","cardiac-magnetic-resonance-stress-perfusion-study-in-patinets-with-fontan-circulation-100572611","NCT06735521","Cardiac Magnetic Resonance Stress-perfusion Study in Patinets with Fontan Circulation","Att Överleva Och Leva Som Vuxen Med Enkammarhjärta I Sverige","CMR_TCPC","Inclusion Criteria:\n\n* Patients who had undergone total cavo-pulmonary connection (TCPC) surgery resulting in Fontan circulation.\n* NYHA (New York Heart Assosiation) class I-II.\n* Understanding the study information (signed informed consent).\n* \\>18 years old.\n\nExclusion Criteria:\n\n* Device therapy (pacemaker, ICD).\n* Failing Fontan (NYHA III-IV).\n* Kidney failure (GFR\\\u003C30ml\u002Fh).\n* Arrythmia (atrial fibrillation).\n* Pregnancy.",{"count":193,"type":21},30,"1 Year","Univentricular heart (UVH) is a severe congenital heart disease. Accurate advanced non-invasive diagnostic methods is limited. Cardiovascular magnetic resonance (CMR) imaging has evolved as a particularly useful tool for the study of patients with adult congenital heart disease (ACHD) considering its ability to determine detailed anatomy and detect early cardiac dysfunction without the need for radiation exposure. Most of contemporary treatment recommendations are based on consensus opinions\u002Fdocuments and small studies from local, or national registries. Improved knowledge is needed in all these areas to facilitate clinical decisions regarding treatment, monitoring and follow-up.\n\nThis study seeks to answer if early detection of deterioration in cardiac function, venous pressure and microvascular dysfunction can identify patients before the symptoms progress and thus help to initiate early treatment. The hypothesis is that quantitative myocardial stress-perfusion maps improves the pathophysiological insight in patients with UVH.\n\nThe overall goal with this research proposal is to implement combined advanced CMR imaging for a comprehensive non-invasive mapping of functional cardiovascular behavior in patients with complex UVH disease. The outcome of this research may benefit this young adult patient population due to early detection of cardiac disease, less hospitalizations because of heart failure, and eventually decrease morbidity and mortality.",[197,34,65,198],"Univentricular Heart","Magnetic Resonance",[200,201,202,203,204,205],"Fontan circulation","CMR","stress-perfusion","tissue characterization","univentricle heart","TCPC","2024-12-13",{"date":208,"type":40},"2024-12-16",{"date":210,"type":40},"2024-04-15",{"date":212,"type":21},"2025-09-01",{"name":214,"class":47},"Karolinska Institutet",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":56,"minAge":4,"maxAge":4,"enrollmentInfo":223,"targetDuration":224,"studyType":60,"phases":4,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":83},"100222972","mainz-intracoronary-database-the-coronary-slow-flow-and-microvascular-diseases-registry-100222972","NCT02180178","Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry","Mainzer IntraCoronAry daTabase (MICAT). Das Coronary Slow Flow- Syndrom Und Koronare Mikrozirkulationsstörungen- Register.","MICAT","Inclusion Criteria:\n\n* clinical indication to coronary angiography\n\nExclusion Criteria:\n\n* none",{"count":160,"type":21},"10 Years","Primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in Mainz. Following amendment of the procol, this study will also include patients who received an Aborb bioresorbable scaffold for the therapy of de novo stenoses.",[227,34],"Coronary Artery Disease",[229,230,231],"microvascular disease","coronary artery disease","Coronary artery disease, with or without microvascular dysfuntion","2024-10-06",{"date":234,"type":40},"2024-10-08",{"date":236,"type":4},"2013-09",{"date":238,"type":21},"2028-09",{"name":240,"class":47},"Johannes Gutenberg University Mainz"]